Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Hansa Biopharma AB
HNSACurrent price
33.02 SEK
-0.08 SEK (-0.24%)
Last closed
32.5 SEK
Company
www.hansabiopharma.com
ISIN
SE0002148817
Sector
Healthcare
Industry
Biotechnology
Exchange
Stockholm Exchange
Capitalization
2 189 854 775 SEK
Yield for 12 month
+24.79 %
1Y
3Y
5Y
10Y
15Y
HNSA
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. Address: ScheelevAegen 22, Lund, Sweden, 223 63
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1 225.61 SEKP/E ratio
–Dividend Yield
–Current Year
+135 955 717 SEK
Last Year
+156 670 371 SEK
Current Quarter
+49 339 629 SEK
Last Quarter
+34 810 680 SEK
Current Year
+70 227 671 SEK
Last Year
+117 659 170 SEK
Current Quarter
+37 801 637 SEK
Last Quarter
-6 279 994 SEK
Key Figures HNSA
1 year
3 years
5 years
10 years
EBITDA
-631 959 035 SEK
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-37.08 %
PEG Ratio
–
Return On Equity TTM
-4176.67 %
Wall Street Target Price
1 225.61 SEK
Revenue TTM
192 019 427 SEK
Book Value
-4.78 SEK
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
113.1 %
Dividend Yield
–
Gross Profit TTM
117 659 171 SEK
Earnings per share
-11.18 SEK
Diluted Eps TTM
-11.18 SEK
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics HNSA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History HNSA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1015:964
Payout Ratio
–
Last Split Date
16.03.2015
Dividend Date
–
Stock Valuation HNSA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
13.5462
Price Sales TTM
11.4043
Enterprise Value EBITDA
-3.8851
Price Book MRQ
8.0531
Financials HNSA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators HNSA
For 52 weeks
22.26 SEK
58.1 SEK
50 Day MA
41.85 SEK
Shares Short Prior Month
–
200 Day MA
39.42 SEK
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart